Table 1 Clinical characteristics of the patients with gliomas used for implantation
Patient ID number | Age range | Sex | WHO grades | WHO classification | Tumor volume (cm3) | IDH1 mutant status | ATRX expression | TP53 expression | Ki67 (%) | 1p/19q deletion (%) | Xenograft formationa |
|---|---|---|---|---|---|---|---|---|---|---|---|
20161128 | 51–55 | F | II | Diffuse astrocytoma, IDHWT | 90 | WT | NA | NA | 30 | NA | Y(P3) |
20170313 | 31–35 | M | II | OGD, NOS | 180 | MUT | NA | NA | 3–5 | NA | N |
20170620 | 56–60 | F | II | Astrocytoma, IDHMUT | 27 | MUT | − | + | 2 | NA | N |
20161109 | 51–55 | M | III | Anaplastic OGD, NOS | 90 | MUT | NA | NA | < 5 | NA | N |
20170612 | 71–75 | M | III | Anaplastic OGD, NOS | 100 | WT | + | + | 20 | 29/17 | Y(P2) |
20170814 | 61–65 | M | III | Anaplastic OGD, IDHMUT-1p/19qc°deleted | 288 | MUT | + | + | 15 | 53/46 | N |
20180129 | 56–60 | M | III | Anaplastic OGD, NOS | 93.24 | WT | + | + | 15 | 73/57 | Y(P3) |
20180521 | 56–60 | M | III | Anaplastic OGD, IDHMUT-1p/19qc°deleted | 180 | MUT | + | + | 20 | 27/34 | Y(P4) |
20161221 | 66–70 | F | IV | GBM, IDHMUT | 80 | MUT | NA | NA | 30 | NA | N |
20170327 | 56–60 | F | IV | GBM, IDHWT | 180 | WT | NA | NA | 15 | NA | Y(P2) |
20170410 | 56–60 | M | IV | GBM (relapse), IDHWT | 120 | WT | NA | + | 20 | NA | Y(P6) |
20170724 | 61–65 | M | IV | GBM, IDHWT | 78.75 | WT | − | + | 30 | 1/5 | Y(P2) |
20180314 | 46–50 | F | IV | GBM, IDHWT | 240 | WT | + | + | 20 | 5/1 | Y(P2) |
20180319 | 66–70 | M | IV | GBM, IDHWT | 180 | WT | + | + | 30 | NA | Y(P5) |
20180408 | 56–60 | M | IV | GBM, IDHWT | 125 | WT | + | + | 50 | NA | Y(P2) |
20180515 | 61–65 | F | IV | GBM, IDHWT | 80 | WT | + | − | 70 | 33/45 | Y(P2) |